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Surface plasmon resonanceFused in sarcoma (FUS) is involved in many processes of RNAmetabolism. FUS and another RNA binding pro-
tein, TDP-43, are implicated in amyotrophic lateral sclerosis (ALS). It is signiﬁcant to characterize the RNA
recognition motif (RRM) of FUS as its nucleic acid binding properties are unclear. More importantly,
abolishing the RNA binding ability of the RRM domain of TDP43 was reported to suppress the neurotoxicity
of TDP-43 in Drosophila. The sequence of FUS-RRM varies signiﬁcantly from canonical RRMs, but the solution
structure of FUS-RRM determined by NMR showed a similar overall folding as other RRMs. We found that
FUS-RRM directly bound to RNA and DNA and the binding afﬁnity was in the micromolar range as measured
by surface plasmon resonance and NMR titration. The nucleic acid binding pocket in FUS-RRM is signiﬁcantly
distorted since several critical aromatic residues are missing. An exceptionally positively charged loop in
FUS-RRM, which is not found in other RRMs, is directly involved in the RNA/DNA binding. Substituting the lysine
residues in the unique KK loop impaired the nucleic acid binding and altered FUS subcellular localization. The re-
sults provide insights into the nucleic acid binding properties of FUS-RRM and its potential relevance to ALS.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Human FUS (fused in sarcoma), also known as TLS (translocated
to liposarcoma), is a member of the TET protein family that also in-
clude EWS (Ewing's sarcoma) and TAF15 (TATA-box binding protein
associated factor 15) [1]. These proteins are predominantly localized
in the nucleus and involved in multiple steps of gene expression
and RNA processing including RNA polymerase II transcription [1,2],
pre-mRNA splicing [3,4], RNA polymerase III transcription repression
[5], DNA repair [6] and mature mRNA transportation in neurons [7].
They could also act as oncogenes by incorporating their N-terminal
regions into the DNA-binding domains of other transcription activa-
tion factors [8]. Attention has been drawn to FUS recently since muta-
tions in FUS have been reported to cause the familial form of the fatalecognition Motif; NLS, nuclear
osis; NMR, nuclear magnetic
oprotein; hnRNP, heteronuclear
wfeng@ibp.ac.cn (W. Feng),
rights reserved.neurodegenerative disease amyotrophic lateral sclerosis (ALS) [9,10].
Interestingly, another RNA binding protein TDP-43 (trans-activating re-
sponse region DNA-binding protein 43), which has similar primary
structural domains as FUS, was also implicated in both familial and spo-
radic ALS [11,12]. Both FUS and TDP43 are involved in gene expression
regulation and RNA processing, suggesting the potential linkage be-
tween the RNA/DNA metabolism and neuronal degeneration [13].
FUS was independently identiﬁed as hnRNP P2 protein [14] capable
of binding to both RNA and single-stranded (ss)/double-stranded (ds)
DNA [15–18]. An in vitro RNA-binding study reported that FUS could
bind to RNAs with a common “GGUG” motif [19]. FUS was also found
to directly interact with a ss human telomeric DNA, although the recog-
nition mode is unclear [20]. The primary sequence of FUS contains an
N-terminal QGSY-rich region followed by a glycine-rich region, an
RRM (RNA recognitionmotif) domain, a C2/C2 zinc ﬁnger motif ﬂanked
by two RG-rich regions and a C-terminal nuclear localization sequence
(NLS) [21–24] (Fig. 1A). The region including the RRM domain, the
RG-rich and the zinc ﬁnger domains was reported to be largely respon-
sible for binding nucleic acids (both RNA and DNA) [17,19,21]. It is de-
batable whether the RRM domain can bind to nucleic acids and what
the recognition mechanism is. One study showed that the RRM domain
of FUS has the ability to bind to RNA [19] while the other study reported
the opposite results [21]. The nucleic acid binding property is critical to
the function of FUS and the related proteins. In fact, abolishing the RNA
Fig. 1. The FUS-RRM domain binds to both RNA and DNA. (A) Domain organization of the FUS protein and the domain boundaries of the constructs used in this study. FUS contains a
QGSY-rich region and a glycine-rich region, a central RRMdomain, a C2/C2 zincﬁngermotif ﬂanked by two RG-rich regions and a C-terminal nuclear localization sequence. (B) An overlay
plot of 1H–15NHSQC spectra of the FUS-RRMdomain (black, both panels) and that of the domain titratedwith RNAUAGUUUGGUGAU (red, left panel) and 24-merDNA d(TTAGGG)4 (red,
right panel), showing signiﬁcant peak shifts.
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niﬁcantly suppressed its neurotoxicity in Drosophila models of TDP-43
mediated ALS [25,26]. Thus, it is important to better understand the
RNA binding properties of FUS in more detail, particularly the RRM do-
main. To achieve this goal, we therefore set to determine the atomic
structure of the RRM domain of FUS.
The RRM domain is a common RNA-binding domain in eukary-
otes, carrying the RNP-featured consensus sequences RNP1 and
RNP2 [27]. Most hnRNP proteins contain one or more RRM domains
that mediate the direct interaction between the nucleic acid and the
proteins to control both RNA processing and gene expression [28]. A
canonical RRM domain has a β1–α1–β2–β3–α2–β4 fold with a
four-stranded β-sheet and two perpendicular α-helices (Supplemen-
tary Fig. S1A). The consensus sequence of RNP1 and RNP2 locate in
the two middle strands β3 and β1, respectively. The complex struc-
tures of the RRM domains from hnRNP A1 (PDB ID: 1UP1), hnRNP D
(PDB ID: 1WTB) and TDP-43 (PDB ID: 3D2W) in complex with DNA
revealed that the nucleic acid binding pocket of the domain is largely
formed by the central four-stranded sheet and enriched with highly
conserved aromatic and positively charged residues (Supplementary
Fig. S1). More importantly, the structural-based sequence alignment
shows that these essential aromatic residues are largely absent in
FUS-RRM (Supplementary Fig. S1B). In particular, the F147 and F149
residues in TDP-43 that were shown to be critical to RNA binding
and TDP-43 toxicity [25] are E336 and T338 in FUS, respectively.
Such dramatic difference prompted us to characterize the structure
and RNA binding properties of FUS-RRM.
Hereby, we report that the FUS-RRM domain can directly bind to
both RNA and DNA in vitro. The solution structure of the FUS-RRMdomain was determined by NMR spectroscopy. The domain adopts
the classical β1–α1–β2–β3–α2–β4 fold but it contains an extra long
loop between α1 and β2. This expanded α1/β2 loop (denoted as
the “KK” loop) contains several evolutionarily conserved lysine resi-
dues and is critical to the nucleic acid binding. Interestingly, the
“KK” loop is absent in the two RRM domains of TDP-43 and other
RRMs. Our results show that the conventional nucleic acid binding
surface formed by the central β1 and β3 sheets is distorted and the
canonical ring stacking interaction is largely absent in FUS-RRM inter-
action with nucleic acids. Instead, the “KK” loop together with other
charged residues constitute a positively charged surface area. NMR ti-
tration experiments determined that the nucleic acid binding site of
the FUS-RRM domain exactly resides at the positively charged surface
area. Binding afﬁnity between FUS-RRM and various forms of nucleic
acid was measured by surface plasmon resonance (SPR) and NMR ti-
tration. Mutating the positively charged residues in the “KK” loop
caused signiﬁcantly reduced nucleic acid binding ability of FUS-RRM
and altered FUS subcellular localization. Hence, this work unequivo-
cally provides mechanistic insights into the nucleic acid binding fea-
tures of the FUS-RRM domain.
2. Materials and methods
2.1. Protein expression and puriﬁcation
The DNA fragment encoding the FUS-RRM domain (residues 278–
385) was cloned into the pET-22b bacterial expression vector be-
tween NdeI and XhoI sites. Point mutations of the FUS-RRM domain
(K312A, K315A/K316A, K312A/K315A/K316A) were created using
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sequencing. Recombinant proteins were expressed in Escherichia coli
Rosetta host cells at 37 °C. The His6-tagged fusion proteins were
puriﬁed by Ni2+-IDA agarose afﬁnity chromatography. The native
FUS-RRM was further puriﬁed by two-step puriﬁcation using the
Heparin column (GE Healthcare) and the Superdex75 column (GE
Healthcare). Uniformly isotope-labeled FUS-RRM was prepared by
growing bacteria in M9 minimal medium using 15NH4Cl as the sole
nitrogen source or 15NH4Cl and 13C6-glucose (Cambridge Isotope Lab-
oratories Inc.) as the sole nitrogen and carbon sources, respectively.
The NMR samples were concentrated to ~0.1–0.15 mM (for titration
experiments) or ~1 mM (for structural determination) in 20 mM
Tris–HCl, 50 mM NaCl, pH 7.0, 0.02% NaN3 and 0.5 mM DSS. Mutant
proteins and NMR samples were prepared using the same protocol
described above.
2.2. NMR spectroscopy
NMR spectra were acquired at 25 °C on a Bruker DXR 600 spectrome-
ter equippedwith a cryogenic probe. The sequential backbone resonance
assignments were achieved by using standard triple-resonance experi-
ments: HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, HNCA [29,30]. Non-
exchangeable side chain resonance assignments were achieved with
the help of the following spectra: HBHA(CO)NH, CCH-TOCSY,
HCCH-TOCSY, HCCH-COSY [30,31]. Approximate inter-proton dis-
tance restraints were derived from three 3D NOESY spectra (all
with 100 ms mixing time): 13C-edited NOESY, 15N-edited NOESY
and 13C-edited NOESY for the aromatic region. The spectra were
processed with the program of NMRPipe [32] and analyzed with
Sparky [http://www.cgl.ucsf.edu/home/sparky/].
2.3. Structure determination and analysis
Structures were calculated using the program CNS [33,34]. Hydro-
gen bonding restraints were generated from the standard secondary
structure of the protein based on the NOE patterns and backbone sec-
ondary chemical shifts. Backbone dihedral angle restraints (ϕ and ψ
angles) were derived from the secondary structure of the protein
and the backbone chemical shift analysis program TALOS [35]. A
total of 400 structures were calculated and the ﬁnal 20 structures
with the lowest total energy and least experimental violations were
selected to represent the FUS-RRM structure. The atomic coordinate
of the FUS-RRM domain has been deposited in the Protein Data
Bank with accession code 2LCW. The protein structure ensemble
was displayed and analyzed with the software of MolMol [36] and
PyMol (http://www.pymol.org/).
2.4. DNA/RNA, NMR titrations and the dissociation constants
The GGUG-containing RNA UAGUUUGGUGAU (Invitrogen), ss te-
lomeric DNAs d(TTAGGG)4 (24-mer) and d(TTAGGG) (6-mer), and a ds
telomeric DNA d(TTAGGG/CCCTAA)4 (ds-DNA) were chemically synthe-
sized and puriﬁed with HPLC by Sangon. The solid DNA/RNA samples
were dissolved in the NMR buffer (20 mM Tris–HCl, 50 mM NaCl, pH
7.0) to make stock solutions of concentrations of 3.5–4.5 mM before ti-
trating into the protein samples. The concentrations of the nucleic acid so-
lutions were calculated from the optical absorbance values. For the
ds-DNA d(TTAGGG/CCCTAA)4 and the ss 24-mer d(TTAGGG)4, the sam-
pleswere heated to 95 °C for 5 min and cooled gradually in roomtemper-
ature overnight to form the duplex and quadruplex conformations.
The possible binding interface residues were determined from the






ð1Þwhere ΔH and ΔN are the chemical shift differences between the free
and bound form of the proton and nitrogen atoms respectively. The








where CSPres is the residue-speciﬁc CSP, CSPavg is the averaged CSP of all
residues and Nres is the number of residues (except those unassigned
and proline residues). The residues with CPSs above the averaged CSP
were considered to be possible binding interface residues. Residues
with CSPs above averaged CSP plus one standard deviationwere consid-
ered having direct contact with the nucleic acid.
The interaction dissociation constant (KD) for the fast exchange
binding process was estimated for separated residues in those
contacting regions described below (in the ‘The nucleic acid binding in-
terface of the FUS-RRM domain’ of the Results section) by curve ﬁtting
the one-site-bind model as in formula (3),
y ¼ Bmax  x
K þ x ð3Þ
where x is the concentration of the DNA/RNA in solution, Bmax is the
maximumCSPwhen ligand concentration is∞,K is the dissociation con-
stant and y is the CSP.
2.5. Surface plasmon resonance (SPR) analysis
The nucleic acid samples used in the SPR analysis had the same se-
quence as those used in the NMR titration experiments above, but
were labeled with a biotin and an AAAAA linker at the 5′-end. All SPR
experiments were carried out at 25 °C using a BIAcore T100 instrument
(GE Healthcare). Streptavidinwas immobilized to a CM5 sensor chip by
the amine-couplingmethod. The biotin-labeledDNA/RNAwas captured
by streptatividin at different channels for 41–104 resonance units (Ru).
The binding experiments were carried out in the running buffer
(20 mM Tirs, pH 7.5, 50 mM NaCl and 0.005% [v/v] Tween 20) at the
ﬂow rate of 30 μl/min.Wild type RRMand eachmutant prepared at var-
ious concentrations in the running buffer were injected over the sensor
surface for 60 s and dissociated for 60 s. Curve ﬁtting was done with
Biacore T100 evaluation software (GE Healthcare). Since the release at
the end of the injection is almost instantaneous, the KD was estimated
by the steady state afﬁnity model.
2.6. Circular dichroism (CD) spectroscopy
The CD spectra of the nucleic acids were collected on a JASCO J-720
CD spectrometer in room temperature. For each sample (300 μl in a
0.1 cm light-path cell), three scans were accumulated in the wave-
length range of 220–340 nm at a scanning rate of 30 nm/min with a
0.5 nm step size. CD data were collected in the unit of millidegrees ver-
sus wavelength. All nucleic acid samples and protein samples were
dissolved in the NMR buffer (20 mM Tris–HCl, 50 mM NaCl, pH7.0)
and the concentrations were 100 μg/ml for the nucleic acids (except
60 μg/ml for the ss 6-mer) and 0.5 mM for the protein. The raw CD
data were subtracted by the buffer or the protein (for the protein/
nucleic acids titrationmeasurements). The CD data was also subtracted
by the zero-position values that were determined by averaging the 10
data points at wavelength 335–340 nm. These data were then smoothed
three times using the 3-point-smoothing method.
2.7. Confocal microscopy
Confocal microscopy was used to determine whether the muta-
tions in the “KK” loop of FUS-RRM affected the subcellular localization
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gelatin-coated 18-mm converslips inside. Various GFP-FUS constructs
were generated and transfected into N2a cells using Lipofectamine
2000 (Invitrogen) as previously published [37]. 24 h after transfection,
cells were ﬁxed in 4% paraformaldehyde, permeabilized by 0.1% Triton
X-100. The nuclei were stained by 4′,6-diamidino-2-phenylindole
(DAPI). The coverslips were mounted and images were acquired
using an Olympus confocal microscope (Olympus Fluoview, Ver.1.7c).
3. Results
3.1. The FUS-RRM domain binds to both RNA and DNA
RNA binding proteins including FUS and TDP-43 are an emerging
group of proteins implicated in neurodegenerative diseases. Given the
signiﬁcant variations of FUS-RRM from canonical RNP1/RNP2 sequences
(Supplementary Fig. S1B) and the controversial nucleic acid-binding ca-
pacities, we ﬁrst puriﬁed the FUS-RRM domain (residues 278–385,
Fig. 1A) and characterized its nucleic acid binding properties by surface
plasmon resonance (SPR) and NMR titration. NMR titration experiments
of FUS-RRM with four different forms of nucleic acid (RNA, ss 6-mer
DNA, ss 24-mer DNA with G-quadruplex secondary structure, and ds
DNA) were performed. Signiﬁcant chemical shift changes were
observed upon the addition of nucleic acids, clearly demonstrating the
direct interaction between the FUS-RRM domain and both RNA and
DNA (Fig. 1B). Furthermore, an independent SPR approachwas employed
tomeasure the interaction between FUS andnucleic acids. The binding af-
ﬁnities (dissociation constants) were calculated from both NMR titration
and SPR approaches and are shown in Table 1. The results from both ex-
periments support that FUS-RRM indeed bound to various forms of
nucleic acids.
3.2. The solution structure of FUS-RRM
To gain more insights into the binding properties of the FUS-RRM
domain, we next determined the 3D atomic structure. Preliminary
crystallization screening of the FUS-RRM domain did not yield useful
crystals, possibly due to several large ﬂexible regions in the domain
(Fig. 2). NMR spectroscopy was consequently employed to determine
the solution structure of FUS-RRM. The excellent 1H–15N HSQC spec-
trum of the FUS-RRM domain demonstrated the high likelihood of
solving the solution structure (Supplementary Fig. S2).
The solution structure of the FUS-RRM domain determined by
NMR spectroscopy is shown in Fig. 2 and Supplementary Table S1
(PDB ID: 2LCW). Except for the N- and C-termini and two loops
(residues 312–320 and 327–332) the overall protein structure was
well deﬁned (Fig. 2A and Supplementary Table S1). The overall
protein topology adopts a canonical β1–α1–β2–β3–α2–β4 fold with
the deﬁned secondary structures connected by ﬁve loops (L1 to L5)
(Fig. 2B). The central β-sheet consists of β1–β4 and rests against a
scaffold comprised of two α-helices (α1 and α2). Sequence alignment
of the FUS-RRM domains from different species reveals that the resi-
dues for the central hydrophobic core packing are highly conserved
(Fig. 2D). Compared to other RRM domains, a signiﬁcant difference
is an extra long L2 between α1 and β2 (residues K312 to P320,
Fig. 2C). This loop is conserved in FUS sequences from all organisms
and within the TET family (Fig. 2D) but absent in other RRMs and
the other ALS related protein TDP-43 (Supplementary Fig. S1B). ThisTable 1
Dissociation constants of FUS-RRM binding with various forms of nucleic acids.
RNA 6-mer 24-mer ds-DNA
SPR determination 132 μM 310 μM 23 μM 227 μM
NMR estimation 146–260 μM 171–209 μM N/Aa 26–43 μM
a Not measured because this is an intermediate exchange process.loop is named as the “KK” loop because of the highly conserved lysine
residues. Interestingly, the “KK” loop protrudes from the central
structure core and resembles an extended arm from the domain and
thus distinctive to other RRM domains (Fig. 2A, B and C).
We next compared the FUS-RRM with three classic RRMs, the
hnRNP D BD2 (1WTB), the hnRNP A1 RRM1 (2UP1), and the RRM2
of mouse TDP-43 (3D2W) (Fig. 2E). Each of the hnRNP RRM domains
can accommodate three or four nucleotides of the telomeric sequence
d(T1T2A3G4G5G6), the d(T2A3G4) or d(T2A3G4G5) [38,39]. The
TDP-43 RRM2 speciﬁcally recognizes the d(T2T3G4) of the 10 mer
DNA d(G1T2T3G4A5G6C7G8T9T10) [40]. As observed in most other
RRM-nucleic acid interactions, the highly conserved aromatic resi-
dues from both the RNP1 and the RNP2 and positively charged resi-
dues from the β1 and the β4 in hnRNP A1 RRM1 directly interact
with DNA through ring stacking and electrostatic interaction/hydrogen
bonding. For instance, most of the solvent exposed residues from the
central sheet of hnRNP A1 RRM1 (K15, F17, D42, M46, F57, F59, E85,
K87) were directly involved in the interaction with the telomeric DNA
[39]. Similarly, the corresponding surface residues in the hnRNP D
BD2 are mostly identical (K183, F185, F225, F227, E253 and K255) ex-
cept for the residues in β2 (D42→S210, M46→P214) that leads to
the loss of recognizing the second guanine (G5) [38] (Fig. 2E). It is
also evident in Fig. 2E that the nucleic acid binding site of RRM2 of
TDP-43 is nearly identical to that of RRM1 of hnRNP A1. In contrast,
the corresponding residues in the corresponding binding surface of
the FUS-RRM domain are quite different. Two conserved Phe residues
in the RNP1 (F57 and F59 in hnRNP A1 RRM1, F225 and F227 in
hnRNP D BD2, F147 and F149 in TDP-43 RRM1 and F229 and F231 in
TDP-43 RRM2) are replaced by E336 and T338 in FUS-RRM. The posi-
tively charged Lys residues in the β1 and the β4 are substituted by
T286 and S367 in FUS-RRM (Fig. 2E). Moreover, these non-canonical
residues E336, T338, T286 and S367 are highly conserved in FUS from
different organisms (Fig. 2D). Therefore, the classical nucleic acid bind-
ing surface of the FUS-RRMdomain is largely disrupted and the binding
feature of FUS-RRM is likely to be different from other canonical RRMs.
3.3. The nucleic acid binding interface of the FUS-RRM domain
To determine the nucleic acid binding features of FUS-RRM, we
performed extensiveNMR titration experiments tomap the exact nucleic
acid binding surface. With addition of the RNA (UAGUUUGGUGAU), a
sub-set of peaks undergoes signiﬁcant chemical shift changes (Supple-
mentary Fig. S3A). Interestingly, a similar sub-set of peak changes were
observed upon addition of various DNA molecules (Supplementary Fig.
S3B-D). Chemical shift perturbation data analysis showed that roughly
ﬁve clusters (residues N284-I287, T313-T317, L324-G331, E336-V339
and A369-N376) are involved in the interaction interface between the
FUS-RRM domain and the nucleic acids (Fig. 3A). It is noted that
E336-V339, which is within in the canonical RNP1 site showed relatively
smaller chemical shift changes as compared to the other four clusters.
The above residues with signiﬁcant chemical shift changes are mapped
to the 3D structure of the FUS-RRM domain. Surprisingly, the nucleic
acid binding surface still resides in the central sheet (Fig. 3B-E) although
the critical aromatic residues in the region of RNP1 (residues K334-F341)
are missing. This is evident when the DNA and RNA binding residues in
FUS-RRM and the BD2 domain of hnRNP D are highlighted side by side
in Supplementary Fig. S4. This suggests that the nucleic acid binding to
FUS-RRM is likely to adopt similar conﬁguration as in other RRMs but
the binding might be weaker or additional structural components
would also contribute to the binding due to the substitution of the crit-
ical aromatic residues in RNP1. Interestingly, the “KK” loop (L2) endures
signiﬁcant changes upon being titrated with all nucleic acids, especially
ds DNA and 24-mer DNA (Fig. 3 and Supplementary Fig. S3). This sug-
gests that this positively charged “KK” loop, which is expanded and
unique in FUS-RRM (Fig. 2C and Supplementary Fig. S1B), is a key site
for the nucleic acid binding. Taken together, although the classical
Fig. 2. The solution structure of the FUS-RRM domain (PDB ID: 2LCW). (A) Stereo-view showing the backbones of 20 superimposed NMR-derived structures of the FUS-RRM do-
main. The ﬂexible N- and C-termini of the protein are removed for clarity. The extra long L2 loop is shown in blue. (B) Ribbon diagram of a representative NMR structure of
FUS-RRM. The secondary structures of FUS-RRM are labeled similarly as in the canonical RRM domain. (C) Superimposed plot of the FUS-RRM domain with other RRM domain
structures randomly selected from the Protein Data Bank (PDB IDs: 1H2V, 1HD0, 1L3K, 1SJQ, 1UP1, 1WF2, 1X4B, 2DH9, 2DO0, 2HGL, 2X1A, 3BS9, 3HI9 and 2DGV). The FUS-RRM
domain contains a long extended L2 loop whereas most of the other RRM domains contain a single residue in the place of this loop. (D) Sequence alignment of the FUS-RRM domain
from different species and RRM domains from human EWS and TAF15. The identical residues are colored in red, highly conserved residues are in green and other residues are in
black. The residue numbers and the secondary structures of human FUS-RRM are marked on the top. The RNP1 and RNP2 regions are enclosed in the red boxes with the consensus
sequence shown at the bottom. The extra long L2 loop (the “KK” loop) is enclosed in a blue box. (E) Ribbon and stick diagrams showing the solvent exposed residues in the central
β-sheets of the RRM1 of the hnRNP A1 interacting with DNA (2UP1) and the corresponding residues in BD2 of the hnRNP D (1WTB), RRM1 of mouse TDP-43 (3D2W) and the RRM
domain of FUS. The central β-sheets were drawn in grey with 50% transparent to emphasize the surface exposing residues. The side chains of the exposed residues are drawn in
explicit atomic model and labeled in red. The DNA fragments are drawn in 50% transparent blue cartoon diagram to show the ring stacking interactions with the aromatic residues
in the RRM domains. 3′ and 5′ end of the DNA fragment are labeled in black.
379X. Liu et al. / Biochimica et Biophysica Acta 1832 (2013) 375–385RNP1 site of FUS-RRM lacks the critical hydrophobic residues and is
largely disrupted, the unique expanded “KK” loop makes additional
contribution to enhance the nucleic acid binding.
Based on the above structural analysis, we propose that the inter-
actions between FUS-RRM and nucleic acids are largely mediated by
charge-charge attractions. The solvent exposed residues on the four-
strand β sheet of FUS-RRM are largely polar residues and accompa-
nied with the positively charged surface areas. Fig. 4A shows the
charged residues on protein surface of FUS-RRM. It is noted that the
highly positively charged “KK” loop contributes signiﬁcantly to the
positively charged surface area. Fig. 4B shows the residues with sig-
niﬁcant chemical shift changes on the protein surface of FUS-RRM.
Compared to the protein surface residues involved in nucleic acid
binding in RRM1 of hnRNP A1 (Fig. 4C) and BD2 of hnRNP D (Fig. 4D),
an expanded positively charged surface area is clearly involved in the
nucleic acid binding.
This binding model is signiﬁcantly different from the canonical
RRM-nucleic acid interaction in which ring stacking between the aro-
matic residues in RRM and bases in nucleic acids is critical. This is
consistent with the earlier sequence analysis that two critical Phe res-
idues in RNP1 of FUS-RRM are missing.
As a control, circular dichroism (CD) was employed to monitor the
conformation of the nucleic acids in the absence and presence of
FUS-RRM. The ss 6-mer, ds-DNA and ss 24-mer showed distinct CD
features consistent with the single-stranded, double-stranded andG-quadruplex structures, respectively (Supplementary Fig. S5A). The
ss G-quadruplex 24-mer DNA had a negative band at 263 nmand a pos-
itive band at 295 nm while the ds-DNA showed a negative band at
240 nmand a positive band at 266 nm [41,42]. Upon addition of various
concentrations of FUS-RRM, no conformational changes of the nucleic
acids were observed. Supplementary Fig. S5B and S5C show the CD
spectra of G-quadruplex 24-mer and ds-DNA, respectively.
3.4. The binding afﬁnity between FUS-RRM and nucleic acids
The binding afﬁnities between FUS-RRM and nucleic acids were
determined by SPR as well as estimated by NMR titration. The NMR
titration curves are shown in Supplementary Fig. S6 and the SPR re-
sponse curves are shown in Supplementary Fig. S7. The binding afﬁn-
ities measured from both approaches are compiled in Table 1. The
relatively low binding afﬁnity with RNA (KD~146–260 μM) suggests
that FUS-RRM may not bind speciﬁc RNA sequences, both of which
could be favorable for its function involved in RNA trafﬁcking and
pre-mRNA splicing (see details in Discussion).
The chemical shift changes in the NMR titration experiments
showed consistent DNA binding surface within FUS-RRM (Fig. 3 and
S3). The afﬁnities of different DNA molecules binding to the FUS-RRM
varied in the range of ~20–200 μM. The shorter ss telomeric DNA
6-mer had a relatively low afﬁnity similar to that of RNA and the KD
values obtained from both methods were consistent (Table 1). The
Fig. 3.Mapping the nucleic acid binding interface of the FUS-RRM domain. (A) The histogram shows chemical shift perturbation proﬁle of each residue of FUS-RRM upon binding to
GGUG containing RNA UAGUUUGGUGAU, 6-mer d(TTAGGG), 24-mer d(TTAGGG)4 and ds-DNA d(TTAGGG/CCCTAA)4. The residues disappeared in titration of 24-mer due to ex-
change broadening are indicated by inverted black triangles. In each panel, the solid, dotted and dashed horizontal lines correspond to the averaged CSP, one and two standard
deviations above the averaged CSP respectively (see the Materials and methods section for details). (B–E) Mapping of the chemical shift perturbation (CSP) induced by RNA (B),
6-mer DNA (C), 24-mer DNA (D) and ds-DNA (E) onto the ribbon diagram of the FUS-RRM domain. The scale of the color scheme is shown at the bottom of each panel. The scales
indicate averaged CSP, averaged CSP plus one standard deviation and averaged CSP plus two standard deviations, respectively, from left to right. Green colored regions in (D) rep-
resent disappeared residues on addition of the 24-mer DNA.
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experiment but a lower afﬁnity (KD~227 μM) in the SPR analysis. The
discrepancy might indicate that multiple binding happened in the pro-
cess, e.g. several protein molecules bound to one ds-DNA. The 24-mer
DNA showed the strongest binding and a medium to slow exchange
NMR spectrum (Fig. 3A), thus no KD was obtained. SPR measured the
KD to be 23 μM,whichwas consistentwith the range of lowmicromolar
suggested by NMR.
As discussed earlier, the multiple positively charged residues on
the nucleic acid binding surface and the “KK” loop suggest that the
nature of the interaction is electrostatic interaction. Such interaction
is consistent with the low-afﬁnity and low-speciﬁcity binding with
multiple forms of nucleic acids observed here. To further support
this conclusion, we determined the salt dependence of the interaction
by performing SPR analysis using buffers containing different salt
concentrations. The KD values shown in Table 2 demonstrate a strong
salt dependence of the interaction. For instance, the KD of the 24-mer
was 23 μM in the presence of 50 mM NaCl, 214 μM in 100 mM NaCl
and 2.5 mM in 200 mM NaCl. The results further support the electro-
static nature of the interaction.
3.5. The unique “KK” loop is essential for nucleic acid binding
The results so far support an intriguing model of FUS-RRM binding
with nucleic acids in which ring stacking makes less contribution
than electrostatic interactions from the protein surface residues.
This model also suggests that the interaction is characteristic of low
afﬁnity and low speciﬁcity, explaining that FUS can bind to various
forms of nucleic acids, from RNA to DNA, from single-stranded to
duplex and G-quadruplex. In particular, the unique “KK” loop in
FUS-RRM, which is absent in other RRM domains, helps to construct
the positively charged surface and makes critical contribution to theelectrostatic interaction with the negatively charged phospho-
backbones of nucleic acids. To test this hypothesis, we made point mu-
tations of the positively charged residues of the “KK” loop: K312A,
K315A/K316A and K312A/K315A/K316A. SPR experiments showed
that the mutation of these lysine residues greatly reduced or abolished
the binding, e.g. the KD of K312A to 24-mer decreased to 103 μM as
compared to 22.9 μM of wild-type RRM. The binding of the K315A/
K316A and K312A/K315A/K316A to nucleic acids decreased so much
that the dissociation constants became un-measurable.
The 1H–15N HSQC spectra of K312A/K315A/K316A mutant in the
presence and absence of nucleic acids were compared to those of
wild-type FUS-RRM (Fig. 5). The mutation caused limited chemical
shift changes in the close neighbors of the mutation sites (Supplemen-
tary Fig. S8), indicating that the global folding of FUS-RRM was mini-
mally impacted by the point mutations. The chemical shift changes
observed in wild-type FUS-RRM upon titration of 24-mer DNA and
RNA are marked with arrows in Fig. 5 (left column). The K312A/
K315A/K316A mutant showed very small chemical shift changes upon
titration of 24-mer DNA or RNA (Fig. 5 right column). The results sup-
port our model that the “KK” loop region plays a critical role in nucleic
acid binding.
3.6. The subcellular localization of FUS-RRM mutants
We next tested whether the “KK” loop mutations would change
the subcellular localization of FUS. We and others have previously
published the C-terminal nuclear localization sequence (NLS) in FUS
[37,43,44]. The NLS is highly effective and mutations outside the
NLS in the context of the full-length FUS always showed a primary lo-
calization in the nucleus (data not shown), thus we tested the “KK”
loop mutant K312A/K315A/K316A in the context of FUS-ΔNLS. As
shown in Fig. 6, wild-type full-length FUS was primarily localized in
Fig. 4. FUS-RRM contains an expanded positively charged surface for nucleic acid binding. (A) Electrostatic surface representation of FUS-RRM shows a prominent positively charged sur-
face area for nucleic acid binding. The positively chargedpotential is in blue and thenegatively chargedpotential is in red. (B) Protein surface of FUS-RRMwith the residueswith signiﬁcant
chemical shift changes uponDNA binding colored in orange. The nucleic acid binding pocket alignswith the positively charged protein surface areas. (C–D) Surface combinedwith ribbon
diagram representations of the hnRNP A1 RRM1/DNA complex (C) and hnRNP D BD2/DNA complex (D). The DNA fragments are drawn in stick representation in red. The protein surface
residues involved in DNA binding in hnRNPD are derived from the CSP [58] and also colored in orangewhile the residues involved in binding in hnRNP A are derived from its X-ray struc-
ture [39] and colored in marine. The surface area involved in nucleic acid binding is larger in FUS-RRM (B) compared to (C) and (D).
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consistent with previous publications. The “KK” loop mutant (FUS-
ΔNLS-AAA) reversed the cytoplasmic accumulation and showedevendis-
tribution in both nucleus and cytoplasm. The result suggests that the “KK”
loopmutationwithout RNA binding capability can either suppress nucle-
ar export or facilitate nuclear accumulation or both.
4. Discussion
This study reconciles the controversy of nucleic acid binding abil-
ity of the RRM domain of FUS and clearly demonstrates that FUS-RRM
can bind both DNA and RNA using both SPR and NMR techniquesTable 2
Salt dependence of the dissociation constants determined by SPR.
Salt concentration 50 mM 100 mM 200 mM
RNA 132 μM 422 μM 4.5 mMa
24-mer 22.9 μM 214 μM 2.5 mMa
ds-DNA 227 μM 2.6 mMa ND
a The mM dissociation constants in the higher salt concentrations (100 mM and
200 mM) were only estimations because the saturation conditions could not be reached
in the analysis.(Table 1; Figs. 1, 3, S3, S6 and S7). Our structural characterization
has also shown two prominent features of FUS-RRM that are different
from the canonical RRM domains: (i) an expanded protein surface
area for nucleic acid binding and (ii) a unique, extra-long, positively
charged “KK” loop that is essential for nucleic acid binding. This
study reveals an intriguing mechanism by which FUS-RRM binds to
nucleic acids.
The canonical RRM domains employ conserved aromatic residues in
the RNP1 and RNP2 motifs to bind ssDNA or RNA primarily through
ring-stacking interactions between the aromatic residues and bases.
However, many such aromatic residues are substituted by polar resi-
dues in FUS-RRM (Fig. 2D), thus ring-stacking is not the primary inter-
action mechanism for the FUS-RRM interaction with nucleic acids. This
also explains that FUS-RRMbinds to ssDNA and RNAwith low sequence
speciﬁcity and low afﬁnity (Table 1). Instead, an extended “KK” loop be-
tweenα1 and β2 is unique in FUS (Fig. 2C). The positively charged “KK”
loop plays a critical role in nucleic acid binding (Fig. 5) and contributes
to the regulation of FUS subcellular localization (Fig. 6). NMR titration
experiments also identiﬁed several auxiliary components that are in-
volved in nucleic acid binding, including the N-terminal region (Q279,
N284, N285, T286), the loop L3 connecting β2 and β3 (L324, Y325,
T326, D328, E330, T331) and the C-terminal ﬂexible part (the region
Fig. 5. The “KK” loop is essential for FUS-RRM interaction with nucleic acid. An overlay plot of the 1H–15N HSQC spectra of the FUS-RRM domain (black) and that of the domain
titrated with nucleic acids (red). The overlaid spectra show the chemical shift changes of the wild-type FUS-RRM (left column) and the K312A/K315A/K316A mutant (right column)
when titrated with the 24-mer DNA (upper row) and RNA (lower row). The peaks with signiﬁcant changes are marked and the changes are highlighted by green arrows in the
spectrum of the wild-type FUS-RRM and the corresponding peaks in the mutant spectra are circled with blue dotted line. The ratio of protein to nucleic acid is labeled on the
top of each spectrum.
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panded protein surface where nucleic acids bind to FUS-RRM likely
through electrostatic interaction (Fig. 4).
Tremendous interest has been focused on understanding the role of
FUS in ALS in recent years. It is particularly interesting that FUS and
TDP-43 are both RNA binding proteins and that both are implicated in
sporadic and familial ALS [11,12]. It is particularly important to charac-
terize the RNA binding properties of the RRM domain because elimina-
tion of the RNA binding of TDP-43 by mutating critical residues in the
RRM domain signiﬁcantly suppressed its neurotoxicity in Drosophila
models of TDP-43 mediated ALS [25,26]. Comparison of the structure
of FUS-RRM determined in this study to the RRM2 domain in TDP-43
[40] reveals signiﬁcant differences. TDP-43 has two RRM domains and
both resemble the canonical RRMs. The phenyalanine residues critical
to ring stacking interaction are conserved in TDP-43 RRM domains.
There is no positively charged “KK” loop in TDP-43 RRM domains.
These signiﬁcant differences between the RRM domains of FUS and
TDP-43 revealed in this study suggest that the pathological etiology
of FUS- and TDP43-mediated ALS may not be exactly identical. The
results from this study also help provide signiﬁcant insights to
guide future studies. For instance, the lysine mutations in the “KK”
loop can be used to examine the signiﬁcance of RNA binding in FUS
neurotoxicity. These studies are currently under investigation in
our laboratories using the Drosophila models that we recently pub-
lished [45].
Our SPR and NMR analysis consistently found the binding afﬁnity
between FUS-RRM and RNA to be in the range of 132 to 260 μM
(Table 1). In contrast, both RRM domains of TDP-43 preferred to
bind to RNA with more UG repeats with a KD in the range of nM
and low μM [40]. Several hundred RNAs have been reported to bind
to TDP-43 [46]. Moreover, the ALS-related TDP-43 mutations could
cause splicing alterations in several hundred message RNAs [46,47].
Most recently, thousands of RNAs were reported as FUS bindingtargets in HEK293 cell line [48] as well as in mouse and human brain
[49]. It is still unknown how many splicing events are mediated by
FUS or what splicing changes are caused by the ALS-related mutations
in FUS. Based on the low binding afﬁnity measured in this study and
the anticipated low sequence speciﬁcity of the FUS-RRM interaction
with RNA, it is not surprising that FUS could bind to a large number of
RNAs. In support of FUS/DNA binding observed in this study, a recent
study demonstrated that FUS can bind to the promoter elements of
many genes [50]. It remains to be determined whether the RRM motif
is the major site of nucleic acid binding in live cells. There is a zinc-
ﬁnger domain located C-terminal of the RRM motif and it is possible
that the zinc-ﬁnger domain may bind nucleic acids with higher
afﬁnity and speciﬁcity. In addition, the RRM motif may also be
involved in protein-protein interaction since its interaction with
nucleic acids is rather weak. The two possibilities will be addressed
in future studies.
A recent study screened 213 human RRM-containing proteins and
found a cohort of RNA-binding proteins that can cause protein aggre-
gation and toxicity when overexpressed in yeast [51]. The study iden-
tiﬁed another TET family member TAF-15 as a potential ALS gene
since point mutations in TAF-15 were found in several ALS patients
but not in healthy controls. The study further suggested that the
third member of the TET family EWS may also harbor mutations in
ALS patients [51]. Other studies showed that TAF-15 and EWS may
be involved in ALS as well [52,53]. Our structural analysis and se-
quence alignment suggest that the RRM domains of FUS, TAF-15
and EWS share the same features: lack of hydrophobic residues for
conventional ring-stacking interaction and existence of an expanded
“KK” loop (Fig. 2D). These features are distinct from the canonical
RRM domains including the two RRM domains in TDP-43. In order
to determine the role of these proteins' RNA binding properties in
ALS disease, it is critical to characterize the RRM domain structure
and to understand the RNA binding mechanism ﬁrst. From this
Fig. 6. The effect of “KK” loopmutation on FUS subcellular localization. TheGFP-taggedwild-type full-length FUS (top), truncated FUSwithout the C-terminal NLS (FUS-ΔNLS,middle) and
the “KK” loop mutant (FUS-ΔNLS-AAA, bottom) were transfected into N2a cells. Representative confocal microscopic images of GFP-FUS and DAPI-stained nucleus are shown. The “KK”
loop mutation reversed the cytoplasmic accumulation of FUS-ΔNLS and showed even distribution in both nucleus and cytoplasm. The scale bar is 10 μm.
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these proteins with similar features in their RRM domains.
Since the cytoplasmic accumulation of FUS, TAF-15 and TDP43 is a
hallmark of the disease, it is conceivable that the RRM domain could
contribute to the pathology of the ALS by inﬂuencing the subcellular
localization of these RNA-binding proteins. An additional possibility
is that the RNA binding property may directly contribute to the phys-
iological function of FUS, TAF-15 and TDP-43 as well as their dysfunc-
tion in disease pathology. Interestingly, the “KK” loop in FUS-RRM is
critical to both RNA binding (Fig. 5) and subcellular localization
(Fig. 6) in our studies. It is noted that the ALS related mutations iden-
tiﬁed so far are clustered in the C-terminal nuclear localization se-
quence (NLS) of FUS. Nuclear targeting by NLS and RNA binding by
RRM are the two distinct but related properties of FUS. It is conceiv-
able that the RNA binding could potentially inﬂuence the subcellular
localization (as evidenced in Fig. 6) and function of FUS and vice
versa. It has been reported that the RRM motif and RNA binding
mediate the nucleocytoplasmic shuttling of RNA binding proteins
[54–56]. For instance, a speciﬁc RRM motif in TIA [54] and La protein
[55] is critical to the nuclear export of the protein. Mutations within
the relevant RRM motif caused accumulation of the protein inside the
nucleus, similar to our observation. However, it is noted that other
RRM motifs may affect the nucleocytoplasmic shuttling differently and
cause the redistribution of the protein in cytoplasm [54–56]. Thus, thespeciﬁc effect of RNA binding on protein subcellular localization needs
to be characterized individually. The signiﬁcance of the RRM domain-
mediated subcellular localization in ALS disease is currently under
investigation.
FUS is a multi-domain protein that binds to nucleic acids and plays a
role in diverse processes in gene expression and RNA metabolism [57].
This study reveals a distinct nucleic acid bindingmechanism in the RRM
domain of FUS. The structural features underline the relatively low
binding afﬁnity to nucleic acids with relatively low sequence speciﬁcity,
which helps understanding its diverse functions. Thousands of RNAs
were recently reported as FUS binding targets [48]. In addition, a recent
study demonstrated that FUS can bind to the promoter elements of
many genes [50]. It is interesting that they found FUS preferentially
bind to single strand DNA complementary to potential G-quadruplex
sequences. The detailed mechanism of FUS binding to the reported se-
quences from the genome-wide studies remains to be further investi-
gated. In summary, the insights obtained from our studies of FUS
binding to various forms of nucleic acids can help design future studies
to better deﬁne the role of FUS in ALS.Conﬂict of interest statement
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